Form 144 filed by Rocket Lab USA Inc. officer Arjun Kampani discloses intent to sell 5,277 common shares on or around 3/17/2025 through Morgan Stanley, with aggregate market value of $99,260 based on NASDAQ pricing. Shares were acquired 3/13/2025 via restricted stock units from the issuer, a standard compensation vesting event. The transaction relies on a Rule 10b5-1 trading plan established 12/12/2024, mitigating insider trading concerns. Kampani reports selling 28,836 shares on 3/14/2025 for $524,276 in the prior three months. He certifies no undisclosed material adverse information about Rocket Lab's operations. As a space launch provider, Rocket Lab's insider activity like this is common for liquidity from equity comp, especially amid growth investments; total shares outstanding exceed 453 million, rendering this negligible.

Minimal near-term impact for RKLB investors as the 5,277-share sale represents <<0.01% of outstanding shares and is routine RSU vesting liquidation under pre-set 10b5-1 plan, avoiding timing concerns. Recent 28k-share sale similarly small. Signals standard comp management, not distress; monitor aggregate insider selling trends and 10-Q/10-K for context amid Rocket Lab's launch cadence and Neutron development.